Androgen Receptor Antagonists

• 

  Subject Areas on Research

  • Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors. 
  • Androgen and androgen receptor antagonist responsive primary African-American benign prostate epithelial cell line. 
  • Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer. 
  • Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations. 
  • Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting. 
  • Beyond aggression: Androgen-receptor blockade modulates social interaction in wild meerkats. 
  • Definition of the cellular mechanisms which distinguish between hormone and antihormone activated steroid receptors. 
  • Development of peptide antagonists for the androgen receptor using combinatorial peptide phage display. 
  • Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. 
  • Enzalutamide in metastatic prostate cancer before chemotherapy. 
  • Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. 
  • Increased survival with enzalutamide in prostate cancer after chemotherapy. 
  • Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer. 
  • Inhibition of androgen receptor-dependent transcriptional activity by DDT isomers and methoxychlor in HepG2 human hepatoma cells. 
  • Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists. 
  • Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis. 
  • Molecular determinants for enzalutamide-induced transcription in prostate cancer. 
  • New data, new paradigms for treating prostate cancer patients--VI: novel hormonal therapy approaches. 
  • Novel therapies are changing treatment paradigms in metastatic prostate cancer. 
  • Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer. 
  • Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort. 
  • Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer. 
  • Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging. 
  • Targeting the androgen receptor--theory and practice. 
  • The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer. 
  • The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists. 
• 

  Keywords of People

  • McDonnell, Donald Patrick, Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, in the School of Medicine, Duke Innovation & Entrepreneurship